HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Snijder, M. B. Articles by Dekker, J. M. Search for Related Content PubMed PubMed Citation Articles by Snijder, M. B. Articles by Dekker, J. M. Social Bookmarking                What's this?

Associations of Adiponectin Levels With Incident Impaired Glucose Metabolism and Type 2 Diabetes in Older Men and Women

The Hoorn Study

¹ Institute of Health Sciences, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
² EMGO Institute, VU University Medical Center Amsterdam, Amsterdam, the Netherlands
³ Internal Medicine, Academic Hospital Maastricht, Maastricht, the Netherlands
⁴ Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, Japan

Address correspondence and reprint requests to Marieke B. Snijder, PhD, Institute of Health Sciences, Vrije Universiteit Amsterdam, De Boelelaan 1085, 1081 HV Amsterdam, Netherlands. E-mail: marieke.snijder{at}falw.vu.nl

OBJECTIVE—Adiponectin is an adipose tissue–derived protein. Low levels are associated with obesity, insulin resistance, and type 2 diabetes. Our objective was to investigate the prospective association between adiponectin levels and the 6.4-year risk of type 2 diabetes and of impaired glucose metabolism (IGM).

RESEARCH DESIGN AND METHODS—The Hoorn Study is a cohort study among Caucasians, aged 50–75 years. BMI, waist-to-hip ratio (WHR), fasting glucose, 2-h glucose, triglycerides, HDL cholesterol, LDL cholesterol, alanine aminotransferase, leptin, and adiponectin were measured at baseline. Lifestyle (alcohol intake, smoking, and physical activity) was assessed by questionnaires. After a mean follow-up of 6.4 years, glucose tolerance was assessed by a 75-g oral glucose tolerance test. Analyses were performed in 1,264 subjects (584 men and 680 women) without type 2 diabetes at baseline. For analyses of incident IGM, 239 subjects with IGM at baseline and/or type 2 diabetes at follow-up were excluded.

RESULTS—Age- and lifestyle-adjusted odds ratios and 95% CIs comparing highest with lowest adiponectin quartile were 0.52 (0.23–1.18) in men and 0.15 (0.06–0.39) in women for type 2 diabetes and 0.90 (0.51–1.61) and 0.28 (0.16–0.48) for IGM, respectively. The risks were only slightly reduced after adjustment for WHR and leptin as markers of (abdominal) adiposity. Adjustment for baseline fasting and postload glucose levels (potential mediators) substantially diminished these inverse associations with type 2 diabetes (0.79 [0.32–1.91] and 0.62 [0.21–1.81]) and with IGM (1.20 [0.61–2.35] and 0.48 [0.26–0.90]), respectively.

CONCLUSIONS—A high adiponectin level was strongly associated with a lower risk of IGM and type 2 diabetes, particularly in women. These results suggest that adiponectin is involved in the pathophysiology linking obesity to type 2 diabetes.

Abbreviations: ALT, alanine aminotransferase • GFR, glomerular filtration rate • HMW, high molecular weight • IGM, impaired glucose metabolism • WHR, waist-to-hip ratio

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. M. Dekker, T. Funahashi, G. Nijpels, S. Pilz, C. D. A. Stehouwer, M. B. Snijder, L. M. Bouter, Y. Matsuzawa, I. Shimomura, and R. J. Heine Prognostic Value of Adiponectin for Cardiovascular Disease and Mortality J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1489 - 1496. [Abstract] [Full Text] [PDF]

				K. J. Mather, T. Funahashi, Y. Matsuzawa, S. Edelstein, G. A. Bray, S. E. Kahn, J. Crandall, S. Marcovina, B. Goldstein, R. Goldberg, et al. Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program Diabetes, April 1, 2008; 57(4): 980 - 986. [Abstract] [Full Text] [PDF]

				J. E. Drew, A. J. Farquharson, S. Padidar, G. G. Duthie, J. G. Mercer, J. R. Arthur, P. C. Morrice, and L. N. Barrera Insulin, leptin, and adiponectin receptors in colon: regulation relative to differing body adiposity independent of diet and in response to dimethylhydrazine Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G682 - G691. [Abstract] [Full Text] [PDF]

				R. Femia, M. Kozakova, M. Nannipieri, C. Gonzales-Villalpando, M. P. Stern, S. M. Haffner, and E. Ferrannini Carotid Intima-Media Thickness in Confirmed Prehypertensive Subjects: Predictors and Progression Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2244 - 2249. [Abstract] [Full Text] [PDF]

				L. Qi, A. Doria, E. Giorgi, and F. B. Hu Variations in Adiponectin Receptor Genes and Susceptibility to Type 2 Diabetes in Women: A Tagging-Single Nucleotide Polymorphism Haplotype Analysis Diabetes, June 1, 2007; 56(6): 1586 - 1591. [Abstract] [Full Text] [PDF]

				S. G. Wannamethee, G. D.O. Lowe, A. Rumley, L. Cherry, P. H. Whincup, and N. Sattar Adipokines and Risk of Type 2 Diabetes in Older Men Diabetes Care, May 1, 2007; 30(5): 1200 - 1205. [Abstract] [Full Text] [PDF]

				A. Wiecek, M. Adamczak, and J. Chudek Adiponectin--an adipokine with unique metabolic properties Nephrol. Dial. Transplant., April 1, 2007; 22(4): 981 - 988. [Full Text] [PDF]